Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma Meeting Abstract
| Authors: | Powles, T.; Choueiri, T. K.; Burotto, M.; Escudier, B.; Bourlon, M. T.; Shah, A. Y.; Suárez, C.; Hamzaj, A.; Porta, C.; Hocking, C.; Kessler, E. R.; Gurney, H.; Tomita, Y.; Bedke, J.; Zhang, J.; Simsek, B.; Scheffold, C.; Apolo, A. B.; Motzer, R. J. |
| Abstract Title: | Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma |
| Meeting Title: | 2022 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2022 Feb 17-19 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-02-20 |
| Language: | English |
| ACCESSION: | WOS:000771008900354 |
| DOI: | 10.1200/JCO.2022.40.6_suppl.350 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 350 -- Meeting was conducted online as well as in person -- Source: Wos |
